DXS INTERNATIONAL PLC
At today's AGM, David Immelman, CEO of DXS International plc, the developer and supplier of clinical decision support solutions to the NHS, will be making the following statement:
We are delighted to announce that after a two and a half year process DXS International is the first of the 13 companies, which were awarded approved supplier agreements with the NHS in 2014, to receive FRA ("full rollout approval"). This means that Groups of GPs can now purchase DXS via a centrally funded initiative.
We have previously indicated that our turnover for the year ending April 2015 had increased by 50% over the previous year and I am pleased to report that for the five months to September 2015 this trend has continued and shows an increase of 42% compared to the same period last year. The current revenue run rate is £3.2 million p.a.
Again during the course of the last financial year, we recruited additional staff to ensure continued delivery of an excellent and compliant service to the NHS which includes enhancements to Support, Clinical Safety, Disaster Recovery, Deployment and Training. To achieve FRA, the Company underwent a comprehensive 8 month due diligence process which included reviews of the requisite systems for the above and passed with flying colours.
The Company is now well positioned to capitalise on the NHS contract and is focused on increasing its sales and marketing activities.
In line with our customer needs, we continue a program of evolving and improving our current products and services as well as developing new products and services, driven by customer and market needs.
We are confident for the future of DXS and look forward to reporting the results for the half year to 31 October 2015 in mid-December.
The Directors of DXS accept responsibility for this announcement
| David Immelman, CE0|
DXS International plc
| 01252 719800 |
| City & Merchant Ltd (Corporate Adviser) || |
| David Papworth|
| 0207 101 7676 |
| MB Communications (Financial PR) || |
| Maxine Barnes || 07860 489571 |
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DXS International plc via Globenewswire